Safety profile of ibuprofen suspension in young children

E Ashraf1, L Ford, R Geetha

  • 1Whitehall-Robins Healthcare, 5 Giralda Farms, 07940-0871, Madison, NJ, USA.

Inflammopharmacology
|July 20, 2007
PubMed

Insights

Ibuprofen and acetaminophen suspensions show similar safety profiles in children for fever and pain relief. Adverse events were rare and mild for both medications across different age groups.

Area of Science:

  • Pediatric pharmacology
  • Clinical safety studies
  • Pain and fever management

Background:

  • Fever and pain are common in children, necessitating safe and effective treatments.
  • Ibuprofen and acetaminophen are widely used analgesics and antipyretics in pediatric populations.
  • Comparative safety data is crucial for guiding clinical decisions in pediatric pain and fever management.

Purpose of the Study:

  • To compare the safety of ibuprofen suspension versus acetaminophen suspension in children.
  • To evaluate adverse events (AEs) associated with ibuprofen and acetaminophen in pediatric patients.
  • To analyze safety data across different age groups (younger and older than 2 years).

Main Methods:

  • A multicenter, open-label, prospective study involving 424 pediatricians and 41,810 children (1 month to 18 years).
  • Safety data collection included medication use and adverse events, categorized by severity and age.
  • Analysis focused on children who received at least one dose of ibuprofen or acetaminophen.

Main Results:

  • Overall incidence of side effects was slightly higher in the ibuprofen group for younger children (17.6% vs. 15.0%) and similar for older children (11.9% vs. 10.7%).
  • Specific AEs were rare (<1%) in both age groups for both treatments; common AEs (>1%) varied by age and treatment.
  • No serious adverse events (e.g., anaphylaxis, Reye's syndrome, GI bleeding) were reported; four unrelated deaths occurred in children under 2 years.

Conclusions:

  • Ibuprofen suspension demonstrates a safe profile in children, including those under 2 years old.
  • The safety profile of ibuprofen in younger children is consistent with its established safety in older children.
  • Ibuprofen exhibits an adverse event profile comparable to acetaminophen in both younger and older pediatric populations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...